$Xtant Medical(XTNT.US)$Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds 25 minutes ago, 5:00 AM EDT Via GlobeNewswire
$Xtant Medical(XTNT.US)$Fourth quarter 2023 revenue grew 84.1% to $28.1 million, compared to $15.3 million for the same quarter in 2022. Full year 2023 revenue grew 58% to $91.3 million, compared to $58.0 million for 2022. These revenue increases are attributed primarily to greater independent agent and private label sales, sales from the acquired Coflex and CoFix product lines, and sales from the acquisition of Surgalign. Gross margin for the fourth quarter of 2023 was 61.0%, co...
The increase in the revolving credit facility and the additional tranche for acquisitions could support Xtant Medical's growth initiatives. The extension of the maturity dates and the reduction in the interest rate could improve the company's financial position.
$Xtant Medical(XTNT.US)$Xtant Medical Announces Record Third Quarter Revenue of $25 Million Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million
The CEO of Xtant Medical, Sean Browne, expressed positivity towards the acquisition, stating it satisfies their acquisition criteria and positions them to enhance manufacturing capabilities, capacity, and cash flows.
Xtant Medical股票討論區
Gross margin for the fourth quarter of 2023 was 61.0%, co...
Raises 2023 Annual Revenue Guidance to $88 Million - $91 Million
暫無評論